Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Harpoon Therapeutics (NASDAQ:HARP – Get Rating) and Codiak BioSciences (NASDAQ:CDAK – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations. Insider and Institutional Ownership 65.5% of Harpoon Therapeutics shares […]
Entera Bio (NASDAQ:ENTX – Get Rating) and Codiak BioSciences (NASDAQ:CDAK – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation. Valuation & Earnings This table compares Entera Bio and […]
Codiak BioSciences (NASDAQ:CDAK – Get Rating) and Century Therapeutics (NASDAQ:IPSC – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations. Institutional and Insider Ownership 71.3% of Codiak BioSciences shares […]
VANCOUVER, British Columbia, May 01, 2023 -- Zymeworks Inc. , a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will... | May 1, 2023
Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks' zanidatamab in key markets, including the U.S., Europe and Japan, pursuant to the license and ...
Gamida Cell (NASDAQ:GMDA – Get Rating) and Codiak BioSciences (NASDAQ:CDAK – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability. Insider and Institutional Ownership 53.4% of Gamida Cell shares […]